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SUMMARY
Suppose that under the conventional randomized clinical trial setting, a new therapy is compared
with a standard treatment. In this article, we propose a systematic, two-stage estimation procedure
for the subject-level treatment differences for future patient’s disease management and treatment
selections. To construct this procedure, we first utilize a parametric or semi-parametric method to
estimate individual-level treatment differences and use these estimates to create an index scoring
system for clustering patients. We then consistently estimate the average treatment difference for
each cluster of subjects via a nonparametric function estimation method. Furthermore, pointwise
and simultaneous interval estimates are constructed to make inferences about such individual-
specific treatment differences. The new proposal is illustrated with the data from a clinical trial for
evaluating the efficacy and toxicity of a three drug combination vs. a standard two drug combination
for treating HIV-1 infected patients.
Keywords: Cross-validation; HIV-infection; Nonparametric function estimation; Personalized medicine;
Subgroup analysis.
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1. INTRODUCTION
One of the major components for modern evidence-based medicine is to utilize the patient’s
“baseline” information for personalized disease management and treatment selection. For instance,
in a recent study it was demonstrated that the benefit of giving toxic chemotherapy prior to hormone
therapy with tamoxifen for postmenopausal women with lymph node-negative breast cancer varies
depending on the estrogen receptor (ER) status of the tumor. Those with ER-negative tumors
benefited substantially from chemotherapy whilst those with ER-positive tumors did not benefit
as compared to receiving tamoxifen alone (IBCSG, 2002). In another example with an observa-
tional study, Sabine (2005) suggested that the efficacy and toxicity profiles for the highly active
antiretroviral therapy (HAART) vary markedly across different subgroups of HIV infected patients
and recommended certain subject-specific treatment strategies. These individualized decision rules
can be extremely useful in practice. However, there are numerous examples that the results from
the so-called subgroup analyses, which were not properly planned or executed subgroup analyses,
could not be validated (Rothwell, 2005; Pfeffer & Jarcho, 2006; Wang et al., 2007).
In this paper, we consider the case that a new therapy was compared with a control under the
standard randomized comparative clinical trial setting. Generally the main goal of a randomized
clinical trial is to make inferences about an overall treatment difference with respect to efficacy
and toxicity. On the other hand, a “positive” trial does not imply that all future patients would
benefit from the new treatment. Moreover, a “negative” study does not mean all patients should
be treated by the standard therapy. In fact, based on the extensive collection of the study patient’s
baseline information from a clinical trial, it would be valuable to utilize such information to make
inferences about the individual-level treatment efficacy.
In practice, a commonly employed first step to perform subgroup analyses is to examine whether
there are statistically significant interactions between the treatment assignment indicator and var-
ious baseline covariates via, for example, parametric regression models (Byar, 1985). This ad hoc
“fishing expedition” approach may not accurately or efficiently identify proper subgroups of pa-
tients who would benefit from the new treatment. Recently, Song & Pepe (2004) proposed a novel
procedure to identify a critical value for a single covariate, which may guide us to split the future
population into two groups. Patients in one group would be treated by the new therapy and those
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in the other group would take the control. Although such a approach is interesting with respect
to an overall utility for the entire population, it does not provide a treatment choice scheme at a
subject-specific level. Moreover, if the treatment difference is not monotonically associated with
this single covariate, such a procedure may not be appropriate. To examine the treatment difference
at a subject-level with a single covariate, Bonetti & Gelber (2000; 2005) clustered the patients with
their covariate values and utilized a moving average procedure to make inferences about the profile
of the treatment differences over the covariate. Recently, in her unpublished thesis, Park (2004)
proposed a procedure to identify patients who may or may not benefit from the new treatment
based on generalized linear models and the Cox proportional hazards models. The validity of her
procedure heavily relies on the model assumptions.
In this paper, we consider the case that each patient has multiple baseline covariates and propose
a systematic, two-stage method to identify patients who would benefit from the new treatment.
Specifically, for the first stage, we use a parametric or semi-parametric model to estimate the
subject-specific mean response for each treatment group. We then utilize the resulting difference of
these two estimates as an index scoring system to cluster patients. That is, subjects in each cluster
would have the same parametric index score. For the second stage, we calibrate the estimated
treatment differences with a consistent, nonparametric function estimation procedure and provide
valid pointwise and simultaneous inferences about the true average treatment difference for each
cluster of patients by controlling the desirable confidence level locally and globally . The new
proposal is illustrated with a data set from a clinical trial for evaluating a three-drug combination
vs. a standard two-drug combination for treating HIV-infected patients. For cost-benefit decision
makings, we also provide the underlying mean treatment response for each treatment group over
the index score and the estimated relative frequency for the parametric score.
2. POINT AND INTERVAL ESTIMATION FOR TREATMENT DIFFERENCES
Suppose that study subjects in a population of interest are randomly assigned to two treatment
groups, {Gk, k = 0, 1}. Let Yk and Uk denote the response Y and the covariate vector U for the
kth group, respectively. Now, suppose that for subjects with U = u, we are interested in estimating
the treatment difference
S(u) = E(Y1 − Y0 | U1 = U0 = u).
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Our data consist of {(Yki,Uki), i = 1, ..., nk}, nk independent and identical copies of (Yk,Uk), k =
0, 1. Assume that as n0 → ∞, the ratio n1/n0 goes to a constant in the open interval (0, 1). To
estimate S(u), one may consider a non-parametric function procedure. In practice, however, when u
is not univariate, generally it is difficult, if not impossible, to estimate S(U) well non-parametrically.
To reduce the complexity of the high dimensional problem, conventionally one utilizes a paramet-
ric or semi-parametric procedure to estimate S(u). For the present case, we consider the following
generalized linear working model to approximate the mean of Yk with a function of Uk:
E(Yk | Uk) = gk(βTkZk), k = 0, 1, (2·1)
where Zk, a p × 1 vector, is a function of Uk with first column being 1, gk is a known, strictly
increasing link function, and βk is an unknown vector of regression coefficients. Note that for
(2.1), we only model the mean function of Y. To estimate the parameter vector βk in (2.1) without
distribution assumptions about the response, one may use a solution β̂k to the following estimating
equation
nk∑
i=1
Zki {Yki − gk(βTZki)} = 0. (2·2)
Using the arguments given in Tian et al. (2007), one can show that β̂k converges to a deterministic
vector β¯k even when Model (2.1) is incorrectly specified. This stability property is crucial for
developing our new procedure. It follows that for a given u or z, a parametric estimator for S(u) is
ŝ(u) = g1(β̂
T
1z)− g0(β̂
T
0z).
Note that when Model (2.1) is correctly specified, β¯k is the true parameter for Model (2.1) and
ŝ(u) is a consistent estimator of S(u).
Let U0 be a typical baseline covariate vector for a future subject from the study population.
If this subject is treated by treatment k, the response is Y 0k , k = 0, 1. For U
0 = u0, we may use
ŝ(u0) to decide which treatment this specific subject should be treated with. The adequacy of such
a decision heavily depends on the appropriateness of Model (2.1). On the other hand, ŝ(·) may be
used as an index scoring system for clustering future subjects with potentially similar treatment
differences. That is, we divide the future population into many strata based on the score ŝ(·) such
that patients in the same stratum have the same parametric score value.
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Now, consider subjects in a stratum such that ŝ(U0) = v, a given value, we are interested in
consistently estimating the average treatment difference
∆¯(v) = µ1(v)− µ2(v),
where µk(v) = E(Y
0
k | ŝ(U0) = v), k = 0, 1, and the expectation is taken with respect the data
and (Y 0,U0). To estimate ∆¯(v), we utilize a nonparametric function estimation procedure for µk(v)
with a local likelihood score function (Tibshirani & Hastie, 1984; Fan & Gijbels, 1996). Specifically,
we obtain the root {âk(v), b̂k(v)} to the local weighted estimating equation, Ŝkv(a, b) = 0, where
Ŝkv(a, b) =
nk∑
i=1
 1
h−1Êkvi
Kh(Êkvi){Yki − g(a+ bÊkvi)} , (2·3)
h is the smoothing parameter, Kh(x) = K(x/h)/h, K(x) is a symmetric kernel function with a finite
support, Êkvi = ψ{ŝ(Uki)} − ψ(v) and ψ(·) is a known, non-decreasing function. Here, g(x) = x if
the response Y is continuous and g(x) = exp(x)/{1 + exp(x)} if Y is binary. Note that we choose
a transformation ψ{ŝ(Uki)} of ŝ(Uki) to implement the smoothing. In practice, a proper choice
of ψ(·) can be critical (Wand et al., 1991; Park et al., 1997). The µk(v) can then be estimated
by µ̂k(v) = g{âk(v)}. This estimator corresponds to the local linear least square estimator for
continuous Y and local linear logistic likelihood estimator for binary Y . Subsequently, we estimate
∆¯(v) as
∆̂(v) = µ̂1(v)− µ̂0(v).
In Appendix A, for h = Op(n
−ν) with 1/5 < ν < 1/2, we show that ∆̂(v) is uniformly consistent
for ∆¯(v), for v in an interval which is properly contained in the support of ŝ(u).
For the above fixed value v, we show in Appendix B that with h = Op(n
−ν) and 1/5 < ν <
1/2, Ŵ(v) = (nh) 12{∆̂(v) − ∆¯(v)} is approximately normally distributed, where n = n0 + n1.
Furthermore, we show that for large n, the distribution of Ŵ(v) can be approximated by the
conditional distribution of a mean-zero normal variable
Ŵ∗(v) =(nh) 12
[∑n1
i=1Kh(Ê1vi){Y1i − µ̂1(v)}Z1i∑n1
i=1Kh(Ê1vi)
−
∑n0
i=1Kh(Ê0vj){Y0j − µ̂0(v)}Z0j∑n0
j=1Kh(Ê0vj)
]
+(nh)
1
2
{
∆̂(v, β̂
∗
1, β̂
∗
0)− ∆̂(v)
}
, (2·4)
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given the data, where Z = {Zki, i = 1, · · · , nk, k = 0, 1} is a random sample from the standard
normal variable and is independent of the data, ∆̂(v, β̂
∗
1, β̂
∗
0) is obtained by replacing β̂k in ∆̂(v)
with β̂
∗
k = β̂k + {
∑nk
i=1 g˙k(β̂
T
kZki)ZkiZ
T
ki}−1[
∑nk
i=1 Zki{Yki − gk(β̂
T
kZki)}Zki], for k = 0, 1, where g˙(·)
is the derivative of g(·). Note that β̂∗k is a solution to the counterpart of estimating equation (2.2),
which is perturbed with the same set of Z in (2.4). Also, note that the Z are the only random
quantities in (2·4), whose distribution can be approximated easily by simulating Z repeatedly. A
(1 − α) pointwise confidence interval estimates for ∆¯(v) can be constructed via this large sample
approximation, which is ∆̂± d(nh)− 12 σ̂(v). Here, σ̂(v) is the standard error estimate of Ŵ∗(v) and
d is the upper (1− α/2) percentile of the standard normal.
To control the global error rate, one may construct a simultaneous confidence band. To make
inference about the treatment differences over a range of v, one may construct a simultaneous
confidence band for {∆¯(v), v ∈ J = [ρl, ρr]}, which is properly contained in the support of ŝ(·). A
conventional way to obtain such a confidence band is based on a sup-type statistic
M̂ = supv∈J
∣∣∣σ̂(v)−1Ŵ(v)∣∣∣ . (2·5)
However, as a process in v, Ŵ(v) does not converge weakly to a proper stochastic process, as n→∞.
Therefore, we cannot use the standard large sample theory for empirical processes to obtain a finite
sample approximation to the distribution of M̂. On the other hand, by the strong approximation
arguments and extreme value limit theorem (Bickel & Rosenblatt, 1973), in Appendix C, we show
that a standardized version of M̂ converges in distribution to a proper random variable. In practice,
for large n, one can approximate the distribution of M̂ by M̂∗, the sup of the absolute value of
Ŵ∗(v) divided by σ̂(v), with (2·4) perturbed by the same set of perturbation variables Z for all
v ∈ J . It follows that the 100(1− α)% simultaneous confidence interval for ∆¯(v) is
∆̂(v)± (nh)−1/2γ σ̂(v), (2·6)
where the cutoff point γ is chosen such that pr(M̂∗ < γ) ≥ 1− α.
As for any nonparametric functional estimation problem, the choice of the smoothing parameter
h for ∆̂(v) is crucial for making inferences about ∆¯(v). It is important to note that for the present
case, we need to choose a single smooth parameter for two nonparametric function estimates, µˆ0(·)
and µˆ1(·). Since each study subject is assigned to a single treatment group, therefore, we cannot use
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the standard cross-validation method with the integrated mean square error criterion to choose h for
∆̂(v). A reasonable, feasible alternative to choose an “optimal” smooth parameter is minimizing an
average squared distance between the observed cumulative treatment difference and their predicted
counterparts in the validation samples under the K-fold cross validation setting. Specifically, we
randomly split the data into K disjoint subsets of about equal sizes, denoted by {Jι, ι = 1, · · · ,K},
where Jι = {Jι1,Jι0} and Jιk denotes the collection of the observations in the ιth subset that belong
to the kth treatment group, for k = 0, 1. For each ι, we use all observations not in Jι to obtain
estimators for the parametric index score and ∆ˆ(v) with a given h. Let the resulting estimators be
denoted by ŝ(−ι)(U) and ∆̂(−ι)(v), respectively. We then use the observations from Jι to calculate
the empirical integrated cumulative square error∫ 
∑
i∈Jι1
I(U1i ≤ u)Y1i∑
i∈Jι1
I(U1i ≤ u)
−
∑
j∈Jι0
I(U0j ≤ u)Y0j∑
j∈Jι0
I(U0j ≤ u)
−
1∑
k=0
∑
i∈Jιk
I(Uki ≤ u)∆̂(−ι)(ŝ(−ι)(Uki))
1∑
k=0
∑
i∈Jιk
I(Uki ≤ u)

2
dĤ(u), (2·7)
where I(·) is the indicator function and Ĥ(u) is an empirical weight function such as the empirical
distribution function. Lastly we sum (2·7) over ι = 1, · · · ,K, and then choose h by minimizing this
sum. It is important to note that since the bandwidth is selected by minimizing a quantity which
is composed of cumulative predicted errors, the order of such optimal bandwidth is expected to be
n−1/3 (Bowman et al., 1998). Thus the selected bandwidth satisfies the condition required for the
resulting functional estimator ∆̂(v) with the data-dependent smooth parameter to have the above
desirable large sample properties.
3. ESTIMATING TREATMENT DIFFERENCES FOR HIV-INFECTED
PATIENTS
We use a data set from a clinical trial conducted by the AIDS Clinical Trials Group (ACTG) to
illustrate the new proposal. Here, we present two cases, the first one is for a continuous response and
the second case is for a binary endpoint. This study, ACTG 320, is one of early studies for examining
the clinical added value from a protease inhibitor with two nucleoside analogues for treating human
immunodeficiency virus type 1 infection (Hammer et al., 1997). A total of 1156 patients were
randomized to two treatment groups. Here, treatment 0 is the two drug combination, zidovudine
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and lamivudine, and treatment 1 is the three drug combination consisting of the above two and
indinarvir. The study was terminated at the second formal interim analysis due to substantial
overall improvements from the three drug combination over the standard two drug combination
with respect to various study endpoints. However, even with this potent new treatment, some
patients may not respond to the therapy, but instead suffer from non-trivial toxicity. Therefore, for
future patients’ disease management, it is important to predict patient’s treatment responses based
on certain “baseline” markers.
For the first example of the illustration, we let the response Y be the patient’s change of CD4
count at Week 24 from the baseline level, an important endpoint for evaluating HIV treatments.
In our analysis, we only considered subjects who had baseline covariate and week 24 CD4 count
values (n0 = 429, n1 = 427). Here, the vector u of baseline covariates consists of CD4, log10RNA
and age. To accommodate the potential non-linear relationship between CD4 and the response,
we let z in Model (2.1) be the vector (1,CD4, log(CD4), log10RNA,Age)
T. Furthermore, we let
g0(·) and g1(·) be the identity function. The estimated regression coefficients for fitted models via
the estimating equations (2·2) are summarized in Table 1(a). It appears that the two resulting
fitted regression functions ŝ(u) are rather different, indicating that there are potential interactions
between the baseline covariates and the treatment response. It is interesting to note that for the two
drug combination group, only age is marginally significant. On the other hand, the baseline CD4
and RNA are highly associated with the response for the three drug combination group. Moreover,
note that younger patients with higher baseline RNA tend to have high scores. For example, among
the 44 patients with age below 40, baseline log10RNA more than 5 and baseline CD4 between 100
and 150, the average score is 95. On the other hand, among the 46 patients with age above 40,
baseline CD4 above 150 and log10RNA below 5, the average score is only 25.
For the second step, we used this continuous score index ŝ(u) to group future patients and predict
the true treatment difference ∆¯(v) for patients with ŝ(U0) = v with ∆̂(v). Here, since the estimated
score has a left skewed distribution, we let ψ(v) = log(− log[Φ{(v−70)/25}]) be the transformation
for choosing the smooth parameter h. The kernel function K(·) is the Epanechnikov kernel and
the smoothing parameter h was obtained through a 10-fold cross validation as a minimizer for the
criterion (2·7). Furthermore, in (2.7), the weight function Ĥ(u) = F̂(u)I(F̂(u) ∈ [0.05, 0.95]), where
F̂(u) = n−1∑1k=0∑nki=1 I(Uki ≤ u). The resulting bandwidth h 0.93 for the transformed score which
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has a range of . Here, the confidence intervals for ∆¯(v) were constructed for the transformed score
ψ(v) ∈ [−1.73, 1.12]. This corresponds to v ∈ [30, 94], which is [ψ−1{ψ(q̂0.01)+h}, ψ−1{ψ(q̂0.99)−h}],
where q̂p is the pth percentile of the observed ŝ(U). In Figure 1(c), we present the estimate ∆̂(v),
the solid curve. This curve, in some region, seems markedly different from the 45-degree line. For
example, subjects with score 60 have an estimated average treatment difference of 45, indicating
that the parametric risk estimates need to be calibrated.
To make further inferences about ∆¯(v), we approximated the distribution of the estimator
∆̂(v) via the aforementioned perturbation-resampling method (2·4) with 500 independent realized
Normal samples of Z. In Figure 1(c), we present the resulting 0.95 pointwise intervals (bounded by
the dotted curves) and its simultaneous band (gray area). For risk-cost-benefit decision makings, we
also present the estimates µˆk, k = 0, 1, the underlying mean changes at Week 24 for both treatment
groups in Figure 1(b). We present the relative frequency of patients in the study population based
on the index score ŝ(u) in Figure 1(a). Since most patients have estimated scores between 50 and
90, the estimation of the true treatment differences tends to be more precise in this region.
The average treatment response from the three drug combination group is uniformly higher
than its counterpart from the two drug combination. However, the treatment differences do not
change much when index score values are low, but for score values higher than 50, the treatment
differences appear to increase significantly. The confidence interval estimates displayed in Figure
1(c) play important roles for treatment selections, especially with additional information regarding
the toxicity profiles over the index score.
For the second example, we considered the patient’s response being a binary variable, which
is one if the week 24 RNA is below 500 copies per milliliter (the criterion for the RNA response
used for ACTG 320). Since the linear effects of the baseline CD4 are almost 0 for both groups,
we only included log(CD4) for this analysis. It follows that z = (1, log(CD4), log10RNA,Age)
′
and g0(x) = g1(x) = exp(x)/{1 + exp(x)} for Model (2.1). Here, n0 = 408 and n1 = 416. In
Table 1(b), we present the estimates for the regression parameters and their estimated standard
errors. For the present case, the estimated score is between -1 and 1, we applied a transformation
ψ(x) = log{(x+1)/(1−x)} for choosing smooth parameter. The optimal bandwidth corresponding
to the transformed score is 0.49 using the 10-fold cross-validation procedure as the one for the
continuous response case. The confidence intervals for ∆¯(v) were constructed over ψ(v) ∈ [0.72, 1.76]
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which corresponds to v ∈ [0.34, 0.71]. In Figure 2(c), we present the estimated treatment differences
(solid curve) over the index score. For this endpoint, the three drug combination is substantially and
uniformly better than the two drug combination as shown in Figure 2(b). For instance, for patients
with a score of 0.35, the probability of having RNA suppressed below the limit of quantification is
46% if treated with the three-drug therapy and only 8% if treated with the two drug alternatives. For
this subgroup, the true treatment difference was estimated as 0.38 with 95% pointwise confidence
interval [0.32, 0.43] and 95% simultaneous confidence interval [0.30, 0.46].
4. REMARKS
Firstly, it is important to note that with the parametric estimate ŝ(u), the corresponding simul-
taneous confidence interval estimates for S(u), if valid, can be quite conservative since they would
be obtained via a sup-statistic over u, whose dimension can be rather large. Secondly, one may
use the same approach presented in this article to estimate individual-specific treatment differences
from an observational study. Such estimates, however, may not have the causal interpretation for
the treatment intervention. Thirdly, the treatment difference may be quantified using other mea-
sures for the contrast between two treatment groups, for example, the relative risk or odds ratio for
binary response variable. Fourthly, using the same idea presented in this article, one may develop
subject-level inference procedures for the treatment differences with a censored event time endpoint.
Lastly, an interesting and important question is how to evaluate the parametric index scoring sys-
tem, which can “efficiently” cluster patients for the first stage of our proposal. Unlike the standard
risk prediction problem, there is no obvious metric such as the receiver operating characteristic
(ROC) curve to evaluate the performance of the index system globally or locally. On the other
hand, heuristically one would choose a scoring system such that its frequency distribution of the
resulting calibrated estimates for the treatment differences has wide spread over a large support.
10
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Appendix
Throughout, unless noted otherwise, we use the notation ' to denote equivalence up to op(1) uni-
formly in v, . to denote being bounded above up to a universal constant, and F˙(x) to denote
dF(x)/dx for any function F . We use P̂k and Pk to denote expectation with respect to the em-
pirical probability measure of {(Yki,Uki), i = 1, · · · , nk} and the probability measure of (Yk,Uk),
respectively. Similarly Ĝk = n
1
2 (P̂k − Pk).
Let pk = limn0→∞ nk/n, β¯k denote the solution to the equation E[Zki{Yki − gk(β′Zki)}] = 0,
s¯(U) = g1(β¯
′
1Z) − g0(β¯′0Z), ψ¯(U) = ψ{s¯(U)} and ψ̂(U) = ψ{ŝ(U)}. We assume that ξ(·), the
density function of ψ¯(U), is continuously differentiable with bounded derivatives and bounded away
from zero on the interval [ψ(ρl), ψ(ρr)], where [ρl, ρr] ⊂ Ωs and Ωs is the support of s¯(U). We also
assume that the marker values are bounded, βk belongs to a compact set Ωβ¯k . For the bandwidth
h, we assume that h = O(n−ν), 1/5 < ν < 1/2.
A Uniform Consistency of ∆̂(·)
To derive the asymptotic properties of ∆̂(·), we first note that from Tian et al. (2007) and Uno
et al. (2007), there exists some deterministic function Ψk such that
n
1
2
k (β̂k − β¯k) = n
− 1
2
k
nk∑
i=1
Ψk(Yki,Zki) + op(1) = Op(1), for k = 0, 1. (A·1)
Since ∆̂(v) = µ̂1(v)− µ̂0(v) = g{â1(v)} − g{â0(v)}, to establish the uniform consistency of ∆̂(v) =
µ̂1(v)− µ̂0(v), it suffices to show that âk(v) is uniformly consistent for ak(v) = g−1{µ¯k(v)},for k = 0
and 1. To this end, we aim to show that d̂k(v) = {d̂ak(v), d̂bk(v)}T = [âk(v) − ak(v), h−1{b̂k(v) −
bk(v)}]T → 0 in probability uniformly in v, where bk(v) = d[g−1{µ¯k(v)}]/dv = ˙¯µk(v)/g˙{ak(v)}. At
any given v, recall that {âk(v), b̂k(v)}T is the root of the estimating equation (2.3). It follows that
d̂k(v) is the solution to the estimating equation
Ŝk(d, v) =
Ŝk1(d; v)
Ŝk2(d; v)
 = n−1 n∑
i=1
 1
h−1Êkvi
Kh(Êkvi){Yki − G(d, v; ψ̂(Uki), h)} = 0
where d = (da, db)
T and G(d, v; y, h) = g[ak(v) + bk(v){y − ψ(v)}+ da + dbh−1{y − ψ(v)}].
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The first step is to show that Ŝk(d; v) is uniformly consistent for
Sk(d; v) =
Sk1(d; v)
Sk2(d; v)
 = ξ(v)
µ¯k(v)− ∫ K(t)g{ak(v) + da + dbt}dt
− ∫ tK(t)g{ak(v) + da + dbt}dt

Since supd,v |Ŝk1(d, v)− Sk1(d, v)| ≤ supv |ε(1)k (v)|+ supd,v |ε(2)k (d, v)|, we first show that
sup
v
|ε(1)k (v)| = Op{(nkh)−
1
2 log(nk)} and sup
d,v
|ε(2)k (d, v)| = Op{(nkh)−
1
2 log(nk)}, (A·2)
where ε
(1)
k (v) = n
−1
k
n∑
i=1
Kh(Êkvi)Yki − ξ(v)µ¯k(v), and
ε
(2)
k (d, v) = n
−1
k
n∑
i=1
Kh(Êkvi)G{d, v; ψ̂(Uki), h)} − ξ(v)
∫
K(t)g{ak(v) + da + dbt}dt.
We only prove the rate of convergence for supd,v |ε(2)k (d, v)| since similar arguments could be used
to establish the rate of convergence for supv |ε(1)k (v)|. To this end, we note that from with (A·1) and
the same arguments as given in Cai et al. (2008),∣∣∣ε̂(2)k (d, v)∣∣∣ . n− 12k (h−1‖Ĝk‖H²+ ∣∣∣∣ ∫ Kh(y − v)dĜk [G{d, v; ψ¯(U), h}I{ψ¯(U) ≤ y}] ∣∣∣∣)
+Op(n
− 1
2
k + h
2)
where H² = {I{g1(β′1z)− g0(β′0z) ≤ y}− I{g1(β¯′1z)− g0(β¯′0z) ≤ y} : ‖β1− β¯1‖+‖β0− β¯0‖ ≤ ², y}
is a class of functions indexed by β0, β1 and y. By the maximum inequality of van der Vaart &
Wellner (1996) and (A·1), we have n−
1
2
k h
−1‖Ĝk‖H² . Op{(nkh)−
1
2 (nkh
2)−
1
4 log(nk)}. On the other
hand, with the standard arguments used in Bickel & Rosenblatt (1973), it can be shown that∣∣∣∣n− 12k ∫ Kh(y − v)dĜk [G{d, v; ψ¯(U), h}I{ψ¯(U) ≤ y}] ∣∣∣∣= Op{(nkh)− 12 log(nk)}.
Therefore, supd,s |ε̂(2)k (d, v)| = Op{(nkh)−
1
2 log(nk)}. This implies (A·2) and hence supd,v |Ŝk1(d, v)−
Sk1(d, v)| = Op{(nkh)− 12 log(nk)} = op(1).
The same arguments as given above can be used to show that supd,s |Ŝk2(d, v) − Sk2(d, v)| =
Op{(nkh)− 12 log(nk)+h} = op(1). Therefore supd,s |Ŝk(d, v)−Sk(d, v)| = op(1). This uniform conver-
gence, coupled with the fact that 0 is the unique solution to the equation Sk(d, v) = 0 with respect
to d and all the eigenvalues of Ak(v) = −∂Sk(d; v)/∂d′|d=0 = ξ(v)g˙{ak(v)}diag{1,
∫
v2K(v)dv} are
uniformly bounded above zero, suggests that supv |d̂k(v)| = Op{(nkh)−
1
2 log(nk)+h} = op(1), which
implies the consistency of µ̂k(v) = g{âk(v)}. Therefore, supv |∆̂(v)− ∆¯(v)| ≤ supv |µ̂1(v)− µ¯1(v)|+
supv |µ̂0(v)− µ¯0(v)| = op(1).
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B Asymptotic distribution of Ŵ(v) = (nh) 12{∆̂(v)− ∆¯(v)}
It follows from a Taylor series expansion that
(nkh)
1
2 d̂ak(v) = (nkh)
1
2{âk(v)−ak(v)} = B̂k1(v)′(nkh) 12 Ŝk(0; v)+Op
{
(nkh)
1
2 (|d̂ak(v)|2 + |d̂bk(v)|2)
}
,
where B̂k1(v) is the first row of B̂k(v) = Âk(v)−1. Using the similar arguments in the previous
section, one can show that B̂k1(v) converges to [ξ(v)−1g˙{ak(v)}−1, 0]T, the first row of Ak(v)−1,
uniformly in v. Furthermore, with the convergence rate of Ŝk(d, v), it is not difficult to show that
the remainder term is bounded by Op{(nkh)− 12 log(nk)2+ (nkh) 12h2} uniformly in v. It follows that
(nkh)
1
2 d̂ak(v) =
(nkh)
1
2 bSk1(0;v)
ξ(v)g˙{ak(v)} +Op{(nkh)−
1
2 log(nk)
2+(nkh)
1
2h2}. Coupled with the convergence rate
of Ŝk1(0; v), we have supv |d̂ak(v)| = Op{(nkh)−
1
2 log(nk)}. Thus,
(nkh)
1
2 d̂ak(v) = [ξ(v)g˙{ak(v)}]−1(nkh)
1
2 P̂k
[
Kh(Êkv){Yk − ηk(v, ψ̂(Uk))}
]
+ op(1).
where ηk(v, y) = g[ak(v) + bk(v){y − ψ(v)}]. We next show that
(nkh)
1
2 d̂ak(v) = (nkh)
1
2 d˜ak(v) + op(1), (B·1)
where (nkh)
1
2 d˜ak(v) = [ξ(v)g˙{ak(v)}]−1(nkh)
1
2 P̂k
(
Kh(Ekv)
[
Yk − ηk{v, ψ¯(Uk)}
])
and Ekv = ψ¯(Uk)−
ψ(v). Noticing the fact that ξ(v)g˙{ak(v)} is bounded away from zero uniformly in v, we have
(nkh)
1
2
∣∣∣d̂ak(v)− d˜ak(v)∣∣∣ . h− 12‖Ĝk‖F² + h− 12‖Ĝk‖H² +Op{(nkh) 12 |β̂1 − β¯1|+ (nkh) 12 |β̂0 − β¯0|+ h2}
where F² =
{
yI{g1(βT1z)−g0(βT0z) ≤ c}−yI{g1(β¯T1z)−g0(β¯T0z) ≤ c} : ‖β1− β¯1‖+‖β0− β¯0| ≤ ², c
}
is the class of functions indexed by β0, β1 and c. By the maximum inequality and (A·1) we have
h−
1
2‖Ĝk‖F² = Op{h−
1
2n−
1
4 log(nk)}. This along with the convergence rate for h− 12‖Ĝk‖H² implies
(B·1). Furthermore, by a delta method and the standard arguments for local linear regression
fitting, we have
Ŵ(v) ' (nh) 12{ξ(v)}−1
(
P̂1 [Kh(E1v) {Y1 − µ¯1(v)}]− P̂0 [Kh(E0v) {Y0 − µ¯0(v)}]
)
(B·2)
which converges to a normal with mean 0 and variance σ1(v)
2 + σ0(v)
2, where
σ2k(v) = m2{pkξ(v)2}−1var{Yk|s¯(Uk) = v} and m2 =
∫
K(v)2dv.
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To justify the resampling method, we first note that since |β̂∗1− β̂1|+ |β̂
∗
0− β̂0| = Op(n−
1
2 ), one
may use the same argument as given above to show that
Ŵ∗(v) =(nh) 12
[∑n1
i=1Kh(Ê1vi){Y1i − µ̂1(v)}Z1i∑n1
i=1Kh(Ê1vi)
−
∑n0
i=1Kh(Ê0vj){Y0j − µ̂0(v)}Z0j∑n0
j=1Kh(Ê0vj)
]
+ op(1).
Furthermore, conditional on the observed data, (nh)
1
2 P̂k[Kh(Êkv){Yk − µ̂k(v)}Z]/P̂k{Kh(Êkv)} is
asymptotical normally distributed with mean 0 and variance
σ̂2k(v) = hP̂k[Kh(Êkv)2{Yk − µ̂k(v)}2]/[pkP̂k{Kh(Êkv)}]2.
It follows from the arguments given in Appendix A to show that σ̂2k(v) converges to σ
2
k(v), as n→∞.
C Justification for the Validity of the Confidence Band for ∆¯(v)
We first justify that after proper standardization, the supermum type statistics M̂ converges weakly.
It follows from (B·2) and the consistency of σ̂(v) for σ(v) that
M̂ = sup
v
∣∣∣∣ (nh) 12 P̂1 [Kh(E1v) {Y1 − µ¯1(v)}]− P̂0 [Kh(E0v) {Y0 − µ¯0(v)}]ξ(v)σ(v)
∣∣∣∣ +op(1).
This, together with the continuity of µ¯k(·) and ξ(v)σ(v), implies that
M̂ = sup
v
∣∣∣∣ n− 12h 12 n∑
j=1
Kh(Evj)Vj
∣∣∣∣ +op(1).
where we rewrite the data as {(Yj,Uj, Gj), j = 1, ..., n} with Gj being the treatment group indicator
for the jth subject, Evj = ψ¯(Uj)− ψ(v), and
Vj = (−1)Gj+1Yj −Gjµ¯1{s¯(Uj)} − (1−Gj)µ¯0{s¯(Uj)}
ξ{s¯(Uj)}σ{s¯(Uj)}
Using similar argument in Bickel & Rosenblatt (1973), we have pr{an(M̂ − dn) < x} → e−2e−x ,
where
an = (2 log[{ψ(ρr)− ψ(ρl)}/h]) 12 and dn = an + a−1n log
{∫
K˙(t)2dt/(4m2pi)
}
.
Now, to justify the resampling procedure for constructing the confidence band, we note that
M̂∗ = sup
v
∣∣∣∣ n− 12h 12 n∑
j=1
Kh(Êvj)V̂jZj + (nh) 12
{
∆̂(v; β̂
∗
1, β̂
∗
0)− ∆̂(v)
} ∣∣∣∣,
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where V̂j is obtained by replacing all the theoretical quantities in Vj by their empirical counterparts.
Again, since |β̂∗1 − β̂1|+ |β̂
∗
0 − β̂0| = Op(n−
1
2 ), from Appendix B, we have
M̂∗ = sup
v
∣∣∣∣ n− 12h 12 n∑
j=1
Kh(Êvj)V̂jZj
∣∣∣∣ +op(1).
It follows from the same argument as given in Tian et al. (2005) that,
sup
x
∣∣∣pr{an(M̂∗ − dn) < x | (Yi,Ui, Gi), i = 1, · · · , n}− e−2e−x∣∣∣→ 0
in probability as n → ∞. Therefore, the conditional distribution of an(M̂∗ − dn) can be used to
approximate the distribution of an(M̂ − dn) for large n.
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Table 1: Estimated regression coefficients and their standard error estimates for the two treatment
groups with the data from ACTG 320.
(a) Continuous outcome: change in CD4 from baseline to week 24
log10RNA CD4 log(CD4) Age
Two Drug
Estimate 3.47 0.04 -0.07 0.44
Std. Error 3.40 0.07 3.91 0.26
Three Drug
Estimate 28.65 -0.24 24.14 -0.22
Std. Error 6.65 0.14 8.05 0.49
(b) Binary outcome: RNA at week 24 ≤ 500 copies/ml
log10RNA log(CD4) Age
Two Drug
Estimate -1.14 -0.31 0.00
Std. Error 0.22 0.16 0.02
Three Drug
Estimate -0.60 0.32 0.06
Std. Error 0.18 0.10 0.01
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Figure 1: (a): The estimated density function of the parametric score with respect to Week 24 CD4
changes; (b): Estimated group averages of Week 24 CD4 changes over the score for two- and three-
drug combination groups; (c): Estimated treatment differences (thick curve), three drug combo
minus two drug combo, with respect to Week 24 CD4 changes over the score, and the corresponding
95% pointwise (dashed curve) and simultaneous (shaded region) confidence intervals.
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Figure 2: (a): The estimated density function of the parametric score with respect to Week 24 HIV-
RNA; (b): Estimated averages of Week 24 RNA over the score for two- and three-drug combination
groups; (c): Estimated treatment differences (thick curve), three drug combo minus two drug combo,
with respect to Week 24 RNA over the score, and the corresponding 95% pointwise (dashed curve)
and simultaneous (shaded region) confidence intervals.
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